Dicot Publishes Investment Memorandum Related to Its Rights Issue
September 2, 2019, Uppsala, Sweden – Dicot AB (”Dicot” or "the Company") has established an investment memorandum related to the Company’s rights issue (the ”Rights Issue”), which was made public on July 23, 2019. The investment memorandum is now available at the Company’s Swedish website, www.dicot.se and will be published on Mangold Fondkommission AB’s website, www.mangold.se.
Application forms and other information about the Rights Issue will be available on the Company's website, www.dicot.se, as well as on Mangold Fondkommission AB’s website, www.mangold.se, from September 3, 2019. The record date in order to receive subscription rights was August 30, 2019. The subscription period will be from September 3 until September 17, 2019.
In the event of an oversubscription of the Rights Issue, the Board of Directors can and will consider an overallotment issue, which is supported by the share issue authorization at the annual general meeting held on May 16, 2019.
The Board of Directors may decide on issuing a maximum of 779 082 shares for a subscription price of SEK 2.60 per share (i.e. a subscription price corresponding to one share in the Rights Issue). The proceeds from the overallotment issue will amount to SEK 2.0 million, if fully exercised. The number of shares may increase by 779,082 shares and the share capital may increase by SEK 97,385.25. The over-allotment issue, when fully subscribed, may imply a dilution of 5.0 percent of the total number of shares in the Company after the over-allotment issue. The Board of Directors will only decide on an over-allotment issue if the Rights Issue is over-subscribed.
Please see the investment memorandum for more information regarding the over-allotment issue.
Mangold Fondkommission AB is acting as financial adviser to the Company in the Rights Issue. Advokatfirman Lindahl KB is acting as the legal adviser to the Company.
For further information, please contact:
Julie Silber, CFO and Director of Investor Relations, Dicot
Tel: +46 79 348 62 77
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin™, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 700 shareholders. For more information see www.dicot.se.
This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the investment memorandum that Dicot is expected to publish on September 2, 2019.
This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.
Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further investment memorandum is established, registered or that any other measure is undertaken beyond that required by Swedish law.
There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.
This press release may contain certain forward-looking information that reflects Dicot's current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. Dicot makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.